vs
Evercore Inc.（EVR）与百利高（PRGO）财务数据对比。点击上方公司名可切换其他公司
Evercore Inc.的季度营收约是百利高的1.2倍（$1.3B vs $1.1B），Evercore Inc.净利率更高（15.7% vs -127.8%，领先143.5%），Evercore Inc.同比增速更快（32.4% vs -2.5%），Evercore Inc.自由现金流更多（$798.6M vs $148.6M），过去两年Evercore Inc.的营收复合增速更高（48.9% vs 1.3%）
Evercore Inc.（前称Evercore Partners）是1995年由罗杰·奥尔特曼、大卫·奥芬森德、奥斯汀·博伊特纳联合创立的全球独立投资银行咨询机构。成立至今，公司已为总规模超4.7万亿美元的并购、重组交易提供专业咨询服务，在全球投行业务领域拥有较高声誉。
百利高（Perrigo）是一家注册于爱尔兰的非处方仿制药生产商，主打自有品牌OTC药品业务。公司70%的净销售额来自美国医疗市场，为优化税务布局将法定总部设在爱尔兰，该地区销售额仅占总营收的0.6%，2013年曾完成美国历史上第六大企业税收倒置交易。
EVR vs PRGO — 直观对比
营收规模更大
EVR
是对方的1.2倍
$1.1B
营收增速更快
EVR
高出34.9%
-2.5%
净利率更高
EVR
高出143.5%
-127.8%
自由现金流更多
EVR
多$650.0M
$148.6M
两年增速更快
EVR
近两年复合增速
1.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $1.1B |
| 净利润 | $204.0M | $-1.4B |
| 毛利率 | — | 32.6% |
| 营业利润率 | 24.2% | -116.0% |
| 净利率 | 15.7% | -127.8% |
| 营收同比 | 32.4% | -2.5% |
| 净利润同比 | 45.2% | -3093.9% |
| 每股收益（稀释后） | $4.80 | $-10.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EVRPRGO
| Q4 25 | $1.3B | $1.1B | ||
| Q3 25 | $1.0B | $1.0B | ||
| Q2 25 | $838.0M | $1.1B | ||
| Q1 25 | $699.0M | $1.0B | ||
| Q4 24 | $979.5M | $1.1B | ||
| Q3 24 | $738.4M | $1.1B | ||
| Q2 24 | $693.4M | $1.1B | ||
| Q1 24 | $585.0M | $1.1B |
净利润EVRPRGO
| Q4 25 | $204.0M | $-1.4B | ||
| Q3 25 | $144.6M | $7.5M | ||
| Q2 25 | $97.2M | $-8.4M | ||
| Q1 25 | $146.2M | $-6.4M | ||
| Q4 24 | $140.4M | $-44.4M | ||
| Q3 24 | $78.4M | $-21.0M | ||
| Q2 24 | $73.8M | $-108.4M | ||
| Q1 24 | $85.7M | $2.0M |
毛利率EVRPRGO
| Q4 25 | — | 32.6% | ||
| Q3 25 | — | 36.1% | ||
| Q2 25 | — | 34.4% | ||
| Q1 25 | — | 37.6% | ||
| Q4 24 | — | 33.9% | ||
| Q3 24 | — | 37.2% | ||
| Q2 24 | — | 37.0% | ||
| Q1 24 | — | 33.1% |
营业利润率EVRPRGO
| Q4 25 | 24.2% | -116.0% | ||
| Q3 25 | 20.8% | 7.0% | ||
| Q2 25 | 18.0% | 4.3% | ||
| Q1 25 | 16.0% | 4.5% | ||
| Q4 24 | 21.8% | 10.0% | ||
| Q3 24 | 16.7% | 7.4% | ||
| Q2 24 | 15.9% | -2.5% | ||
| Q1 24 | 14.8% | -5.1% |
净利率EVRPRGO
| Q4 25 | 15.7% | -127.8% | ||
| Q3 25 | 13.8% | 0.7% | ||
| Q2 25 | 11.6% | -0.8% | ||
| Q1 25 | 20.9% | -0.6% | ||
| Q4 24 | 14.3% | -3.9% | ||
| Q3 24 | 10.6% | -1.9% | ||
| Q2 24 | 10.6% | -10.2% | ||
| Q1 24 | 14.6% | 0.2% |
每股收益（稀释后）EVRPRGO
| Q4 25 | $4.80 | $-10.23 | ||
| Q3 25 | $3.41 | $0.05 | ||
| Q2 25 | $2.36 | $-0.06 | ||
| Q1 25 | $3.48 | $-0.05 | ||
| Q4 24 | $3.32 | $-0.32 | ||
| Q3 24 | $1.86 | $-0.15 | ||
| Q2 24 | $1.81 | $-0.79 | ||
| Q1 24 | $2.09 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.0B | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.0B | $2.9B |
| 总资产 | $5.4B | $8.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EVRPRGO
| Q4 25 | $3.0B | — | ||
| Q3 25 | $2.4B | $432.1M | ||
| Q2 25 | $1.7B | $454.2M | ||
| Q1 25 | $1.4B | $409.9M | ||
| Q4 24 | $2.4B | $558.8M | ||
| Q3 24 | $1.8B | $1.5B | ||
| Q2 24 | $1.7B | $542.8M | ||
| Q1 24 | $1.4B | $658.5M |
股东权益EVRPRGO
| Q4 25 | $2.0B | $2.9B | ||
| Q3 25 | $1.8B | $4.4B | ||
| Q2 25 | $1.7B | $4.5B | ||
| Q1 25 | $1.5B | $4.4B | ||
| Q4 24 | $1.7B | $4.3B | ||
| Q3 24 | $1.6B | $4.6B | ||
| Q2 24 | $1.5B | $4.5B | ||
| Q1 24 | $1.4B | $4.7B |
总资产EVRPRGO
| Q4 25 | $5.4B | $8.5B | ||
| Q3 25 | $4.4B | $10.1B | ||
| Q2 25 | $3.7B | $10.1B | ||
| Q1 25 | $3.3B | $9.8B | ||
| Q4 24 | $4.2B | $9.6B | ||
| Q3 24 | $3.6B | $11.2B | ||
| Q2 24 | $3.3B | $10.4B | ||
| Q1 24 | $3.0B | $10.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $807.5M | $175.4M |
| 自由现金流经营现金流 - 资本支出 | $798.6M | $148.6M |
| 自由现金流率自由现金流/营收 | 61.6% | 13.4% |
| 资本支出强度资本支出/营收 | 0.7% | 2.4% |
| 现金转化率经营现金流/净利润 | 3.96× | — |
| 过去12个月自由现金流最近4个季度 | $1.2B | $145.1M |
8季度趋势，按日历期对齐
经营现金流EVRPRGO
| Q4 25 | $807.5M | $175.4M | ||
| Q3 25 | $560.9M | $51.7M | ||
| Q2 25 | $437.7M | $75.9M | ||
| Q1 25 | $-549.7M | $-64.5M | ||
| Q4 24 | $686.4M | $312.6M | ||
| Q3 24 | $234.5M | $42.2M | ||
| Q2 24 | $348.5M | $9.5M | ||
| Q1 24 | $-281.2M | $-1.4M |
自由现金流EVRPRGO
| Q4 25 | $798.6M | $148.6M | ||
| Q3 25 | $541.5M | $29.8M | ||
| Q2 25 | $411.7M | $56.7M | ||
| Q1 25 | $-569.3M | $-90.0M | ||
| Q4 24 | $673.1M | $274.9M | ||
| Q3 24 | $226.6M | $15.1M | ||
| Q2 24 | $340.7M | $-18.9M | ||
| Q1 24 | $-282.3M | $-26.5M |
自由现金流率EVRPRGO
| Q4 25 | 61.6% | 13.4% | ||
| Q3 25 | 51.8% | 2.9% | ||
| Q2 25 | 49.1% | 5.4% | ||
| Q1 25 | -81.4% | -8.6% | ||
| Q4 24 | 68.7% | 24.2% | ||
| Q3 24 | 30.7% | 1.4% | ||
| Q2 24 | 49.1% | -1.8% | ||
| Q1 24 | -48.3% | -2.4% |
资本支出强度EVRPRGO
| Q4 25 | 0.7% | 2.4% | ||
| Q3 25 | 1.9% | 2.1% | ||
| Q2 25 | 3.1% | 1.8% | ||
| Q1 25 | 2.8% | 2.4% | ||
| Q4 24 | 1.4% | 3.3% | ||
| Q3 24 | 1.1% | 2.5% | ||
| Q2 24 | 1.1% | 2.7% | ||
| Q1 24 | 0.2% | 2.3% |
现金转化率EVRPRGO
| Q4 25 | 3.96× | — | ||
| Q3 25 | 3.88× | 6.89× | ||
| Q2 25 | 4.50× | — | ||
| Q1 25 | -3.76× | — | ||
| Q4 24 | 4.89× | — | ||
| Q3 24 | 2.99× | — | ||
| Q2 24 | 4.72× | — | ||
| Q1 24 | -3.28× | -0.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EVR
| Advisory Fees | $1.1B | 87% |
| Commissions And Related Revenue | $66.5M | 5% |
| Underwriting Fees | $49.5M | 4% |
| Other | $29.6M | 2% |
| Investment Management | $23.2M | 2% |
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
